Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

SRPT – Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc.
SRPT
$51.91
Name : Sarepta Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $5,036,683,776.00
EPSttm : 2.34
finviz dynamic chart for SRPT
Sarepta Therapeutics, Inc.
$51.91
4.63%
$2.52

Float Short %

5.33

Margin Of Safety %

Put/Call OI Ratio

0.64

EPS Next Q Diff

1.21

EPS Last/This Y

7.01

EPS This/Next Y

5.23

Price

54.38

Target Price

165.36

Analyst Recom

1.43

Performance Q

-56.14

Relative Volume

3.03

Beta

0.85

Ticker: SRPT




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-10SRPT99.760.631.0529236
2025-03-11SRPT100.70.631.7829406
2025-03-12SRPT99.790.630.5129533
2025-03-13SRPT98.370.6320.3729587
2025-03-14SRPT97.120.631.8629585
2025-03-17SRPT101.360.630.3929238
2025-03-18SRPT73.20.620.5330034
2025-03-19SRPT79.950.510.2050633
2025-03-20SRPT73.430.470.7054730
2025-03-21SRPT74.090.480.5756699
2025-03-24SRPT76.330.580.4635990
2025-03-25SRPT73.630.581.4936858
2025-03-26SRPT72.840.600.4338204
2025-03-27SRPT71.820.600.5040351
2025-03-28SRPT70.40.530.5142220
2025-03-31SRPT63.770.540.4739422
2025-04-01SRPT61.880.510.5642216
2025-04-02SRPT62.490.515.9044136
2025-04-03SRPT58.670.723.8750746
2025-04-04SRPT54.40.640.3450573
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-10SRPT99.76138.31447.710.20
2025-03-11SRPT100.69138.31522.310.20
2025-03-12SRPT99.72164.81488.410.67
2025-03-13SRPT98.37164.81479.210.67
2025-03-14SRPT97.19164.81483.010.67
2025-03-17SRPT101.35164.81582.410.97
2025-03-18SRPT73.54164.81014.410.97
2025-03-19SRPT79.97164.81660.510.97
2025-03-20SRPT73.4589.01358.710.45
2025-03-21SRPT74.13-19.01295.49.35
2025-03-24SRPT76.33-19.01328.29.35
2025-03-25SRPT73.61-19.01225.29.35
2025-03-26SRPT72.88-19.01265.49.35
2025-03-27SRPT71.82-19.01258.19.35
2025-03-28SRPT70.41-19.01250.39.35
2025-03-31SRPT63.82-19.01134.79.35
2025-04-01SRPT61.91-19.01235.29.35
2025-04-02SRPT62.47-19.01295.19.35
2025-04-03SRPT58.61-19.01184.39.35
2025-04-04SRPT54.38-19.01168.29.35
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-10SRPT-0.213.215.39
2025-03-11SRPT-0.213.215.39
2025-03-12SRPT-0.213.215.55
2025-03-13SRPT-0.213.215.55
2025-03-14SRPT-0.253.215.55
2025-03-17SRPT-0.253.225.55
2025-03-18SRPT-0.253.225.56
2025-03-19SRPT-0.253.225.56
2025-03-20SRPT-0.253.225.56
2025-03-21SRPT-0.253.225.56
2025-03-24SRPT-0.253.215.56
2025-03-25SRPT-0.253.215.56
2025-03-26SRPT-0.253.215.33
2025-03-27SRPT-0.253.215.33
2025-03-28SRPT-0.253.215.33
2025-03-31SRPT-0.253.205.33
2025-04-01SRPT-0.253.205.33
2025-04-02SRPT-0.253.205.33
2025-04-03SRPT-0.253.205.33
2025-04-04SRPT-0.253.205.33
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

1.5

Avg. EPS Est. Current Quarter

0.59

Avg. EPS Est. Next Quarter

2.71

Insider Transactions

-0.25

Institutional Transactions

3.2

Beta

0.85

Average Sales Estimate Current Quarter

693

Average Sales Estimate Next Quarter

761

Fair Value

Quality Score

87

Growth Score

83

Sentiment Score

23

Actual DrawDown %

70.1

Max Drawdown 5-Year %

-67.2

Target Price

165.36

P/E

22.84

Forward P/E

4.24

PEG

0.26

P/S

2.78

P/B

3.45

P/Free Cash Flow

EPS

2.38

Average EPS Est. Cur. Y​

9.35

EPS Next Y. (Est.)

14.58

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

12.37

Relative Volume

3.03

Return on Equity vs Sector %

-4.4

Return on Equity vs Industry %

8.6

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.85

EBIT Estimation

1168.2
Sarepta Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 1372
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
stock quote shares SRPT – Sarepta Therapeutics, Inc. Stock Price stock today
news today SRPT – Sarepta Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SRPT – Sarepta Therapeutics, Inc. yahoo finance google finance
stock history SRPT – Sarepta Therapeutics, Inc. invest stock market
stock prices SRPT premarket after hours
ticker SRPT fair value insiders trading